Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
PLoS One. 2011;6(12):e28487. doi: 10.1371/journal.pone.0028487. Epub 2011 Dec 12.
To optimize the antitumor activity of oncrasin-1, a small molecule identified through synthetic lethality screening on isogenic K-Ras mutant tumor cells, we developed several analogues and determined their antitumor activities. Here we investigated in vitro and in vivo antitumor activity of NSC-743380 (1-[(3-chlorophenyl) methyl]-1H-indole-3-methanol, oncrasin-72), one of most potent analogues of oncrasin-1.
In vitro antitumor activity was determined in NCI-60 cancer cell line panel using cell viability assay. In vivo antitumor activity was determined in parallel with NSC-741909 (oncrasin-60) in xenograft tumors established in nude mice from A498, a human renal cancer cell line. Changes in gene expression levels and signaling pathway activities upon treatment with NSC-743380 were analyzed in breast and renal cancer cells by Western blot analysis. Apoptosis was demonstrated by Western blot analysis and flow cytometric analysis. NSC-743380 is highly active against a subset of cancer cell lines derived from human lung, colon, ovary, kidney, and breast cancers. The 50% growth-inhibitory concentration (GI(50)) for eight of the most sensitive cell lines was ≤ 10 nM. In vivo study showed that NSC-743380 has a better safety profile and greater antitumor activity than NSC-741909. Treatment with NSC-743380 caused complete regression of A498 xenograft tumors in nude mice at the tested doses ranging from 67 mg/kg to 150 mg/kg. Mechanistic characterization revealed that NSC-743380 suppressed the phosphorylation of C-terminal domain of RNA polymerase II, induced JNK activation, inhibited JAK2/STAT3 phosphorylation and suppressed cyclin D1 expression in sensitive human cancer cells. Blocking JNK activation or overexpression of constitutively active STAT3 partially blocked NSC-743380-induced antitumor activity.
NSC-743380 induces antitumor activity through modulation of functions in multiple cancer related pathways and could be a potential anticancer agent for some solid tumors.
为了优化 oncrasin-1 的抗肿瘤活性,我们通过对同源 K-Ras 突变肿瘤细胞进行合成致死筛选,开发了几种类似物,并确定了它们的抗肿瘤活性。在这里,我们研究了 oncrasin-72(1-[(3-氯苯基)甲基]-1H-吲哚-3-甲醇),oncrasin-1 的一种最有效的类似物之一,在体外和体内的抗肿瘤活性。
使用细胞活力测定法在 NCI-60 癌症细胞系组中测定体外抗肿瘤活性。在裸鼠中建立 A498(人肾癌细胞系)异种移植肿瘤的同时,用 NSC-741909(oncrasin-60)进行体内抗肿瘤活性测定。通过 Western blot 分析分析了处理 NSC-743380 后乳腺癌和肾癌细胞中基因表达水平和信号通路活性的变化。通过 Western blot 分析和流式细胞术分析证明了细胞凋亡。NSC-743380 对源自人肺、结肠、卵巢、肾和乳腺的癌症细胞系具有高度活性。八种最敏感细胞系的 50%生长抑制浓度(GI(50))≤10 nM。体内研究表明,与 NSC-741909 相比,NSC-743380 具有更好的安全性和更大的抗肿瘤活性。在测试剂量为 67mg/kg 至 150mg/kg 时,NSC-743380 可使 A498 异种移植肿瘤在裸鼠中完全消退。机制特征表明,NSC-743380 抑制 RNA 聚合酶 II C 末端结构域的磷酸化,诱导 JNK 激活,抑制 JAK2/STAT3 磷酸化并抑制敏感人癌细胞中环素 D1 的表达。阻断 JNK 激活或过表达组成型激活的 STAT3 部分阻断了 NSC-743380 诱导的抗肿瘤活性。
NSC-743380 通过调节多个与癌症相关的通路中的功能诱导抗肿瘤活性,可能成为某些实体瘤的潜在抗癌药物。